

## HYDROGENATION OF BORYLATED ARENES


D. Moock<sup>§</sup>, M. Wollenburg<sup>§</sup>, F. Glorius

Organisch-Chemisches Institut, Corrensstraße 40, 48149 Münster, Germany

<sup>§</sup>These authors contributed equally.

In pharmaceutical drug discovery flat, aromatic molecules are the predominant species, mainly because of their easy preparation.<sup>[1]</sup> At the same time natural products and substances that pass clinical trials have an increased C<sub>sp<sup>3</sup></sub> fraction.<sup>[2]</sup> Hence, the stereoselective transformation of accessible aromatic compounds into saturated (hetero-)cycles is a desirable task.

Utilising the previously reported Rh-complex **1**<sup>[3]</sup> we were able to develop a highly efficient, *cis*-selective method for the hydrogenation of abundant aryl boronic acids and their derivatives, opening a route to access versatile saturated boronate products as new building blocks to be explored in pharmaceutical research. The reaction proceeds with various boron-protecting groups and is tolerant of a variety of functional groups. The utility of the corresponding saturated cyclic building blocks was shown by post-functionalisation of the boron group.



[1] D. G. Brown, J. Boström, *J. Med. Chem.* **2016**, *59*, 4443–4458.

[2] F. Lovering, J. Bikker, C. Humblet, *J. Med. Chem.* **2009**, *52*, 6752–6756.

[3] a) V. Lavallo, Y. Canac, C. Präsang, B. Donnadiou, G. Bertrand, *Angew. Chem. Int. Ed.* **2005**, *44*, 5705–5709. b) Y. Wei, B. Rao, X. Cong, X. Zeng, *J. Am. Chem. Soc.* **2015**, *137*, 9250–9253. c) M. P. Wiesenfeldt, Z. Nairoukh, W. Li, F. Glorius, *Science* **2017**, *357*, 908–912.